MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
2.340
0.000
0.00%
Opening 15:44 06/06 EDT
OPEN
2.310
PREV CLOSE
2.340
HIGH
2.370
LOW
2.300
VOLUME
387.43K
TURNOVER
734.36K
52 WEEK HIGH
3.570
52 WEEK LOW
0.9547
MARKET CAP
93.01M
P/E (TTM)
-1.2559
1D
5D
1M
3M
1Y
5Y
Spruce Biosciences, Inc.: [Amend]General statement of acquisition of beneficial ownership
Press release · 05/30 21:05
Spruce Biosciences, Inc.: Current report
Press release · 05/26 22:09
BRIEF-Spruce Biosciences Appoints Percival Barretto-Ko To Board Of Directors
Reuters · 05/25 12:50
Oppenheimer Reiterates Spruce Biosciences (SPRB) Outperform Recommendation
NASDAQ · 05/23 21:58
Oppenheimer Remains a Buy on Spruce Biosciences (SPRB)
TipRanks · 05/23 12:35
Oppenheimer Reiterates Outperform on Spruce Biosciences, Maintains $8 Price Target
Benzinga · 05/23 11:39
Spruce Biosciences, Inc.: Statement of changes in beneficial ownership of securities
Press release · 05/20 11:36
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Spruce Biosciences (SPRB) and Centessa Pharmaceuticals (CNTA)
TipRanks · 05/17 00:40
More
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The Company is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS) with adrenal dysfunction. The Company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with highly elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction.

Webull offers kinds of Spruce Biosciences Inc stock information, including NASDAQ:SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.